Chimeric Mouse Model for the Infection of Hepatitis B and C Viruses

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Tesfaye, Abeba ^a   Stift, Judith ^b   Maric, Dragan ^c   Cui, Qingwen ^a   Dienes, Hans Peter ^b   Feinstone, Stephen M ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HUMAN ALBUMIN; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIMERA; CONTROLLED STUDY; ENGRAFTMENT; GENOTYPE; HEMIZYGOTE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFECTION SENSITIVITY; INOCULATION; LIVER CELL; MOUSE; MOUSE MODEL; NEWBORN DEATH; NONHUMAN; PHENOTYPE; PROMOTER REGION; SCID MOUSE; TRANSGENE; TRANSGENIC MOUSE; VIRUS INFECTIVITY; VIRUS MUTANT; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

AGING; ANIMALS; CHIMERA; DISEASE MODELS, ANIMAL; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; MICE; MICE, SCID; MICE, TRANSGENIC; PAN TROGLODYTES; PROTEINS; RNA, VIRAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84885404327     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077298     Document Type: Article

References (32)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, et al. (2006) The prevalence of Hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: 705-714. doi:10.7326/0003-4819-144-10-200605160-00004. PubMed: 16702586.
2. Momin B, Richardson L, (2012) An Analysis of Content in Comprehensive Cancer Control Plans that Address Chronic Hepatitis B and C Virus Infections as Major Risk Factors for Liver Cancer. J Community Health 37: 912-916. doi:10.1007/s10900-011-9507-y. PubMed: 22160788.
3. Yamashita T, Honda M, Kaneko S, (2011) Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection. J Gastroenterol Hepatol 26: 960-964. doi:10.1111/j.1440-1746.2011.06723.x. PubMed: 21443660.
4. McGivern DR, Lemon SM, (2011) Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 30: 1969-1983. doi:10.1038/onc.2010.594. PubMed: 21258404.
5. Peter Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, et al. (2005) A Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973. doi:10.1002/hep.20819. PubMed: 16149085.
6. Bukh J, (2012) Animal Models for the Study of Hepatitis C Virus Infection and Related Liver Disease. Gastroenterology 142(6):: 1279-1287. doi:10.1053/j.gastro.2012.02.016. PubMed: 22537434.
7. Billerbeck E, de Jong Y, Dorner M, de la Fuente C, Ploss A, (2013) Animal models for hepatitis C. Curr Top Microbiol Immunol 369: 49-86. doi:10.1007/978-3-642-27340-7_3. PubMed: 23463197.
8. Houghton M, (2011) Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 239: 99-108. doi:10.1111/j.1600-065X.2010.00977.x. PubMed: 21198667.
9. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, et al. (2012) Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366(3):: 216-224. doi:10.1056/NEJMoa1104430. PubMed: 22256805.
10. Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, et al. (2010) Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376(9751):: 1467-1475. doi:10.1016/S0140-6736(10)61384-0. PubMed: 20951424.
11. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, et al. (2012) Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55(3):: 742-748. doi:10.1002/hep.24724. PubMed: 21987462.
12. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, et al. (2001) Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7: 927-933. doi:10.1038/90968. PubMed: 11479625.
13. Petersen J, Dandri M, Gupta S, Rogler CE, (1998) Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc Natl Acad Sci U_S_A 95: 310-315. doi:10.1073/pnas.95.1.310. PubMed: 9419372.
14. Vanwolleghem T, Libbrecht L, Hansen BE, Desombere I, Roskams et al,. (2010) Factors determining successful engraftment of hepatocytes and susceptibility of hepatitis B and C virus infection in uPA-SCID mice. J Hepatol 53: 468-476. doi:10.1016/j.jhep.2010.03.024. PubMed: 20591528.
15. Brezillon NM, DaSilva L, L'Hôte D, Bernex F, Piquet J, et al. (2008) Rescue of Fertility in Homozygous Mice for the Urokinase Plasminogen Activator Transgene by the Transplantation of Mouse Hepatocytes. Cell Transplant, 17: 803-812. doi:10.3727/096368908786516800. PubMed: 19044207.
16. Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, et al. (2007) Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 25: 903-910. doi:10.1038/nbt1326. PubMed: 17664939.
17. Grompe M, Al-Dhalimy M, Finegold M, Ou CN, Burlingame T, et al. (1993) Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 7: 2298-2307. doi:10.1101/gad.7.12a.2298. PubMed: 8253378.
18. Grompe M, Lindstedt S, Al-Dhalimy M, Kennaway NG, Papaconstantinou J, et al. (1995) Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet 10: 453-460. doi:10.1038/ng0895-453. PubMed: 7545495.
19. Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, et al. (2010) Human liver chimeric mice provide A model for hepatitis B and C virus infection and treatment. J Clin Invest 120(3):: 924-930. doi:10.1172/JCI40094. PubMed: 20179355.
20. Weglarz TC, Degen JL, Sandgren EP, (2000) Hepatocyte transplantation into diseased mouse liver: Kinetics of parenchymal repopulation and identification of the proliferative capacity of tetraploid and octaploid hepatocytes. Am J Pathol 157: 1963-1974. doi:10.1016/S0002-9440(10)64835-3. PubMed: 11106569.
21. Heo J, Factor VM, Uren T, Takahama Y, Lee JS, et al. (2006) Hepatic precursors derived from murine embryonic stem cells contribute to regeneration of injured liver. Hepatology 44(6):: 1478-1486. doi:10.1002/hep.21441. PubMed: 17133486.
22. Bukh J, Meuleman P, Tellier R, Engle RE, Feinstone SM, et al. (2010) Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver chimeric mouse models. J Infect Dis 201(9):: 1381-1389. doi:10.1086/651579. PubMed: 20353362.
23. Tabor E, Purcell RH, London WT, Gerety RJ, (1983) Use of and Interpretation of Results Using Inocula of Hepatitis B Virus with Known Infectivity Titers. J Infect Dis 147(3):: 531-534. doi:10.1093/infdis/147.3.531. PubMed: 6833797.
24. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309(5734):: 623-626. doi:10.1126/science.1114016. PubMed: 15947137.
25. Puig M, Mihalik K, Yu MY, Feinstone SM, Major ME, (2002) Sensitivity and reproducibility of HCV quantitation in chimpanzee sera using TaqMan real-time PCR assay. J Virol Methods 105(2):: 253-263. doi:10.1016/S0166-0934(02)00119-2. PubMed: 12270658.
26. Major ME, Mihalik K, Fernandez J, Seidman J, Kleiner D, et al. (1999) Long-Term Follow-Up of Chimpanzees Inoculated with the First Infectious Clone for Hepatitis C Virus. J Virol 73(4):: 3317-3325. PubMed: 10074186.
27. Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, et al. (2002) Previously Infected and Recovered Chimpanzees Exhibit Rapid Responses That Control Hepatitis C Virus Replication upon Rechallenge. J Virol 76(13):: 6586-6595. doi:10.1128/JVI.76.13.6586-6595.2002. PubMed: 12050371.
28. Reed LJ, Muench H, (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493-497.
29. Institute of Medicine of the National Academies(2011) Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity. Report Brief.
30. Pearson T, Shultz LD, Miller D, King M, Laning J, et al. (2008) Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment. Clin Exp Immunol 154(2):: 270-284. doi:10.1111/j.1365-2249.2008.03753.x. PubMed: 18785974.
31. Cao X, Shores EW, Hu-Li J, Anver MR, Kelsall BL, et al. (1995) Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 2(3):: 223-238. doi:10.1016/1074-7613(95)90047-0. PubMed: 7697543.
32. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE, (1992) RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68(5):: 869-877. doi:10.1016/0092-8674(92)90030-G. PubMed: 1547488.